KIMS Q3 results: revenue up 29% YoY; Rs 100 Cr more for Sunshine stake increase

Revenue Growth 20pctExceptional ItemResults View source PDF Explain this filing

KIMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+9.2%Reaction day

₹594.55

prior close

₹594.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+2.5%+6.6% vs market

Hospital peers, median of 23sector+1.6%+7.6% vs sector

On the reaction day the stock moved 6.6 pts more than Nifty Smallcap 250 and 7.6 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+0.5

15m

-0.2

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+9.2+2.5+6.6+1.6+7.6

Next day

+9.5+3.1+6.5+1.2+8.3

+15.5+3.2+12.4+4.4+11.2

+16.5+2.4+14.1+2.1+14.4

+14.4+0.8+13.6+1.7+12.7

+14.6+0.7+13.9+3.4+11.2

+17.5+2.0+15.5+6.4+11.2

15d

+21.0-1.8+22.8+4.0+17.0

+16.2-5.0+21.2-0.1+16.3

+11.2-2.3+13.5+0.1+11.0

+30.7+8.8+21.9+10.4+20.3

UpDownMarket · Nifty Smallcap 250Sector · Hospital peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

KIMS reported Q3 FY26 consolidated revenue of Rs 997.7 Cr, up 29% YoY from Rs 772.4 Cr. Nine-month revenue rose 26% to Rs 2,830 Cr. However, Q3 PAT fell to Rs 51.9 Cr from Rs 92.5 Cr, and 9M PAT declined to Rs 208.9 Cr from Rs 308.7 Cr. Board approved raising acquisition limit by Rs 100 Cr for further stake increase in material subsidiary Sarvejana Healthcare (Sunshine Hospital), where KIMS currently holds 75.53%. Auditor issued unmodified review report.

Likely market impact

Strong revenue growth on acquisitions but margins compressed by higher finance and depreciation costs; further stake buy planned in subsidiary.